Ali McBride

Clinical Associate Professor

University of Arizona College of Pharmacy

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ali McBride is a Clinical Associate Professor at The University of Arizona College of Pharmacy, USA. His research focuses on oncology pharmacy, specifically examining the economic implications and effectiveness of cancer treatments, including BRCA testing and chemotherapy regimens. Recent articles highlight challenges in identifying patient cohorts within administrative claims and evaluate treatment comparisons in acute myeloid leukemia and other cancers.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (2)

Thomas LeBlanc

Associate Professor of Medicine

Duke University School of Medicine

UNITED STATES

View details

David DeRemer

Clinical Associate Professor

University of Florida

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ali McBride

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm

Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment

The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer

The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention

National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey

Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia

Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy

Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer

Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients

Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report

Collaborators (2)

Thomas LeBlanc

David DeRemer

Make your next move.